Request Demo

Last update 16 May 2025

Esmolol Hydrochloride

Last update 16 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-esmolol, (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate, 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester

+ [16]

Target

β1-adrenergic receptor

Action

antagonists

Mechanism

β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

Diabetic foot ulcerVentricular ArrhythmiaHypertension+ [2]

Inactive Indication-

Originator Organization

Baxter International, Inc.

Active Organization

HQ Specialty Pharma Corp.Baxter Healthcare Corp.

NovaLead Pharma Pvt Ltd.

+ [1]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (31 Dec 1986),

HypertensionTachycardia, SupraventricularTachycardia

Regulation-

Structure/Sequence

Molecular FormulaC16H26ClNO4

InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N

CAS Registry81161-17-3

188

Clinical Trials associated with Esmolol Hydrochloride

NCT06958393

/ Not yet recruitingPhase 4IIT

Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery: a Single-centre, Prospective, Randomized Controlled Trial

Background Postoperative delirium (POD) is a common acute and transient form of brain dysfunction in elderly patients following surgery that can lead to serious adverse clinical outcomes and even death. Although existing studies have preliminarily investigated the effects of opioid-free anaesthesia (OFA) on POD, high-quality evidence on these effects for elderly patients undergoing gastrointestinal surgery remains limited. This study aims to investigate the effects of OFA on the development of POD in elderly patients following gastrointestinal surgery.
Methods and analysis:
This single-centre, prospective, randomized controlled trial will be conducted at the First Affiliated Hospital of Shandong First Medical University, China. A total of 406 patients aged 65 years or older who are scheduled for elective gastrointestinal surgery will be randomly allocated to receive either opioid-free anaesthesia (OFA; dexmedetomidine, esmolol, and esketamine) or conventional opioid-based anaesthesia (OBA). The primary outcome is the incidence of POD 7 days after surgery. The secondary outcomes are all-cause mortality within 30 days after surgery, intraoperative haemodynamic changes, the 15-item quality of recovery (QoR-15) scores at 24 h, 48 h, and 72 h after surgery, complications during postoperative hospitalization, pain numerical rating scale (NRS) score at 72 h after surgery, incidence of nausea and vomiting at 72 h after surgery, morphine milligram equivalent for analgesics at 72 h after surgery, duration of anaesthesia (from induction to discontinuation), duration of surgery (from skin incision to the last suture), duration of post-anaesthesia care unit (PACU) stay, and length of hospital stay.
Discussion:
The results of this study may shed light on the effects of OFA on POD in elderly patients undergoing gastrointestinal surgery. The study is designed on the basis of the following key hypothesis: the use of opioid drugs for anaesthesia may increase the risk of POD through mechanisms such as blood-brain barrier destruction, neuroinflammatory responses, and central nervous system depression. Through the single-centre and prospective design of this randomized controlled trial, this study will directly analyse differences in the effects of OFA and conventional OBA on the incidence of POD, haemodynamic stability and long-term cognitive function in elderly patients.
gastrointestinal surgery.

Start Date20 May 2025

Sponsor / Collaborator

Qianfoshan Hospital of Shandong Province

CTRI/2025/03/082812

/ Not yet recruitingPhase 3IIT

A randomised study to compare the effects of i.v Esmolol vs i.v Labetalol in attenuating hemodynamic response during extubation in Department of Anesthesia, S.M.S Medical College Jaipur - nil

Start Date22 Mar 2025

Sponsor / Collaborator-

ChiCTR2500096874

/ SuspendedNot ApplicableIIT

The effects of esmolol on intraoperative stress response and inflammatory response in orthopedic surgery patients

Start Date13 Feb 2025

Sponsor / Collaborator-

100 Clinical Results associated with Esmolol Hydrochloride

100 Translational Medicine associated with Esmolol Hydrochloride

100 Patents (Medical) associated with Esmolol Hydrochloride

2,348

Literatures (Medical) associated with Esmolol Hydrochloride

31 Dec 2025·ANNALS OF MEDICINE

Effects of esketamine infusion on tourniquet-induced hypertension in patients undergoing below-knee orthopedic surgery: protocol for a randomized controlled trial

Article

Author: Ying, Yao-yu ; Shi, Hai-jing ; Ji, Fu-hai ; Jiang, Kai ; Peng, Ke ; Zhao, Wen-qian ; Zhuang, Min-yuan

INTRODUCTION:

Application of a tourniquet reduces surgical bleeding while causing pain and tourniquet-induced hypertension (TIH). Deeper anesthesia and additional opioids are often insufficient to mitigate TIH but are associated with prolonged recovery and complications. Herein, we describe the protocol for a clinical trial investigating whether intraoperative esketamine infusion would reduce the rate of TIH during below-knee orthopedic surgery.

PATIENTS AND METHODS:

This prospective, randomized, double-blind, controlled trial will include a total of 80 adults scheduled for below-knee orthopedic surgery under general anesthesia. Patients will be randomly assigned in a 1:1 ratio to receive either esketamine infusion at 0.25 mg/kg/h or normal saline infusion after anesthesia induction and during tourniquet inflation. Both groups will receive ultrasound-guided unilateral popliteal sciatic nerve block and adductor canal block with 0.25% ropivacaine. The primary outcome is the occurrence of TIH, defined as an increase in systolic blood pressure >30% of baseline during tourniquet inflation. Secondary outcomes include the incidence of hypotension during surgery; intraoperative hemodynamic changes; intraoperative opioid dose and total amount of esmolol; postoperative nausea and vomiting, dizziness, and mental side effects; postoperative pain at 1, 6, 12, and 48 h after surgery; postoperative analgesic consumption within 48 h after surgery; and length of postoperative hospital stay. Additionally, we will assess patients' quality of recovery at 24 h after surgery.

DISCUSSION:

This trial will determine the effects of esketamine infusion on TIH in patients who undergo below-knee orthopedic surgery under general anesthesia. Our results will offer a new insight into optimizing anesthetic care for surgical patients receiving tourniquet.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2400081237).

01 Aug 2025·TALANTA

Fabrication and evaluation of stationary phases with different morphology from two imidazole-based ligands for nonchiral and chiral electrochromatographic separation

Article

Author: Bai, Liming ; Gao, Lidi ; Chen, Mo ; Liang, Xinyu ; Zhao, Ming ; Zhao, Fuquan ; Liu, Shuren ; Qin, Shili ; Hou, Yuanyuan ; Chu, Hongtao

In this work, two metal-organic porous materials from the two imidazole-based ligands (4-methylimidazole-5-carbaldehyde (aImeIm) and histidine (His)) and the same metal source (Zn(CH₃COO)₂·2H₂O), namely His-ZIF-93 with a crystal zeolite imidazolate framework and His/aImeIm@Zn with an amorphous networks, were first designed and synthesized by the one-pot method. They were used as the stationary phases (SPs) of open-tubular capillary electrochromatography (OT-CEC) to evaluate and compare their separation performance for the nonchiral and chiral compounds. His-ZIF-93-bonded OT-CEC column successfully separated five families of nonchiral analytes due to the synergistic effect of His and the crystal framework. The separation mechanism included electrostatic interaction, molecular sieve effect, π-π interaction, electrophoretic mobility, hydrogen bonding interaction, and so on. His/aImeIm@Zn-bonded OT-CEC column exhibited a more superior enantioseparation capability for seven chiral compounds with an ultrahigh column efficiency of 7.6 × 10⁵ plates/m due to a large number of chiral sites and the porous networks. Enantioseparation were attributed to the difference of adsorption and selectivity between the SPs and the two enantiomers through the adsorption experiments and the binding constants tests. Thus, both His-ZIF-93-bonded OT-CEC column and His/aImeIm@Zn-bonded OT-CEC column demonstrated the universality for the analytes, as well as excellent reproducibility, satisfactory stability and long lifetime.

01 Apr 2025·Journal of Veterinary Cardiology

Ventricular tachycardia as the main manifestation of primary cardiac lymphoma in a dog

Article

Author: Marconato, L ; Romito, G ; Turba, M E ; Morini, M

An 11-year-old Cocker spaniel was referred with a one-day history of lethargy. Upon presentation, cardiac auscultation revealed a tachyarrhythmia. Two-dimensional transthoracic echocardiography with concurrent electrocardiographic tracing showed biventricular systolic dysfunction, mild left atrial dilation, functional mitral and tricuspid regurgitations, and sustained wide-complex monomorphic tachycardia (heart rate: 330 beats per minute), primarily consistent with ventricular tachycardia. Laboratory test results were unremarkable, except for an elevated serum concentration of cardiac troponin I (2.84 ng/mL). Initially, despite the intravenous administration of lidocaine and esmolol, cardioversion was not achieved. Oral amiodarone was subsequently added to the antiarrhythmic protocol, resulting in the restoration of sinus rhythm, followed by an improvement in the dog's clinical condition and biventricular systolic function on repeated echocardiographic examination. Accordingly, the dog was discharged from the hospital on amiodarone therapy. However, four days later, the dog returned with a relapse of symptomatic ventricular tachycardia. Despite prompt management, the dog succumbed to the progression of ventricular tachycardia into ventricular fibrillation. Interestingly, although repeated echocardiographic examinations did not reveal abnormalities suggesting a cardiac tumor, macroscopic and histological findings led to the diagnosis of primary cardiac lymphoma of T-cell origin. This case contributes to the currently limited scientific literature on primary cardiac lymphoma in dogs. Moreover, it contributes to raising awareness among veterinary cardiologists about the potential limitations of two-dimensional transthoracic echocardiography in detecting cardiac lymphoma in dogs, as well as the possible arrhythmogenic role of this rare condition in the species.

News (Medical) associated with Esmolol Hydrochloride

04 Jan 2024

·www.biospace.com

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

More new product innovations in 2023, as compared to 26 in 2022 13 new products launched in the fourth quarter of 2023 BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022. In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables. New injectable products added include potassium phosphate vials, tranexamic acid and esmolol intravenous bags. These launches provide a strong foundation for higher injectable revenues going forward. In addition, Amneal launched several key new retail products in the fourth quarter, including spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules. “We are pleased to have brought an impressive number of new products to market in 2023,” said Dr. Srinivas Kone, Senior Vice President, Generics R&D. “Our R&D portfolio prioritizes complex and high-value products that provide better access to affordable medicines for providers and patients.” About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations, including international expansion; expected or estimated operating results and financial performance; the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our ability to complete the proposed holding company reorganization on the anticipated timeline or at all and to realize the expected benefits of such reorganization; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain highly skilled personnel; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. View source version on businesswire.com: Contacts Investors: Anthony DiMeo Head of Investor Relations anthony.dimeo@amneal.com Source: Amneal Pharmaceuticals, Inc. View this news release online at:

20 Dec 2022

·www.biospace.com

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

- 8 new product launches in Q4 closes out another successful year of innovation - First approval of a large volume bag product signals further expansion of injectables business BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution. “2022 was another successful year of innovation for Amneal. Across the portfolio we continue to innovate, further expand our portfolio of essential medicines, and drive incremental impact and benefit for health care professions and their patients. Looking to 2023, we expect more than 30 new product launches,” said Chirag Patel and Chintu Patel, Amneal Co-Chief Executive Officers. In addition, Amneal also announced it received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (“FDA”) for its first large volume bag, esmolol hydrochloride in sodium chloride injection. Harsher Singh, SVP for Amneal Biosciences, stated, “We are seeing continued momentum in expanding our injectables business. We are excited about this first ready to use bag approval utilizing one of our new manufacturing sites and look forward to more over the coming months.” Esmolol hydrochloride in sodium chloride injection is indicated for tachycardia. For full prescribing information, see package insert located here. According to IQVIA®, U.S. annual sales for this product for the 12 months ended October 2022 were $57 million. About Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance, the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and expenditures. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry, in general, specifically from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods and any associated supply chain disruptions; existing and future legal proceedings, the outcome of which are uncertain and may divert management resources and require us to incur substantial defense or settlement payments and costs; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the impact of severe weather; the impact of the ongoing COVID-19 pandemic, and the emergence of variant strains; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to FDA product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; the impact of global economic conditions, including any economic effects stemming from adverse geopolitical events, an economic downturn, inflation and rising interest rates; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Drug Approval

100 Deals associated with Esmolol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00644	Esmolol Hydrochloride	C07AB09	DB00187

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic foot ulcer	India	NovaLead Pharma Pvt Ltd.	24 Apr 2024
Ventricular Arrhythmia	Japan	Maruishi Pharmaceutical Co., Ltd.	08 Oct 2002
Hypertension	United States	Baxter Healthcare Corp.	31 Dec 1986
Tachycardia	United States	Baxter Healthcare Corp.	31 Dec 1986
Tachycardia, Supraventricular	United States	Baxter Healthcare Corp.	31 Dec 1986

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04181606 (CTgov)	Early Phase 1	-	30	Isometric handgrip exercise+Esmolol infusion (Esmolol Infusion)	bcjmqdtfji(bincykqsiq) = rtfvgipidh odjmrfdafu (rixzwglxtc, 3.2) View more	-	13 May 2025
				Saline infusion (Saline Infusion)	bcjmqdtfji(bincykqsiq) = qamdoivhtq odjmrfdafu (rixzwglxtc, 2.4) View more
NCT04356352 (CTgov)	Phase 2/3	Pain \| Injection Site Reaction	33	Lidocaine (Lidocaine)	psecxivpjs(zhjknftfdy) = vdwdcgznkh wcibnxzrae (zndhfxxbnz, 0.66) View more	-	19 Sep 2024
				Esmolol (Esmolol)	psecxivpjs(zhjknftfdy) = illlkuzvub wcibnxzrae (zndhfxxbnz, 1.02) View more
NCT01113515 (CTgov)	Phase 1/2	Diabetic foot ulcer	44	Placebo gel (Placebo)	spbexuapkm = dfmjlwldai encpbiuwvh (zelrrnshoy, xuukzmqalx - fcxhdllhsu) View more	-	20 May 2024
				Esmolol hydrochloride (Galnobax 20% QD)	spbexuapkm = kgjnzdjusc encpbiuwvh (zelrrnshoy, bulgpcghnm - dsfkapvaaa) View more
NCT03998436 (CTR/2018/11/016295 \| ###DELETE, CTgov)	Phase 3	Diabetic foot ulcer	176	Esmolol Hydrochloride (Galnobax® 14% Gel Plus SoC)	onxkkpqlfv = ntfugmvtid uzldwhcvao (mdvgknohaj, zcjspihrth - agkxnkvrgq) View more	-	22 Sep 2023
				Only Standard of Care (SoC Only)	onxkkpqlfv = jrpbxlqaqz uzldwhcvao (mdvgknohaj, vkosnvxark - pcygqftcvd) View more
NCT03998436 \| CTRI/2018/11/016295 (Pubmed)	Phase 3	Diabetic foot ulcer	176	Esmolol with SoC	vwsqrhdfnm(mrkvkgrcxt) = yvwnojgnme tmcfsvuogr (nyxkfcmkte ) View more	-	01 May 2023
				Topical Esmolol Hydrochloride (SoC only)	vwsqrhdfnm(mrkvkgrcxt) = lgfufcgxts tmcfsvuogr (nyxkfcmkte ) View more
CTRI/2013/07/003838 \| NCT01113515 (Pubmed)	Phase 1/2	Diabetic foot ulcer	-	Galnobax 14%	bsnwfthmdt(evksterrht) = tzzespemci mhnlpjriss (rhwbxwzktb ) View more	-	16 Oct 2022
				Galnobax 20%	bsnwfthmdt(evksterrht) = rclbtsiuef mhnlpjriss (rhwbxwzktb ) View more
NCT02369900 (Pubmed)	Phase 2	Shock, Septic	40	Esmolol	szdjjwyupv(povcszjaax) = hswxpphfax ydsavlnplk (swbmirgrcd )	-	27 Dec 2021
				Placebo	szdjjwyupv(povcszjaax) = ontlgusmle ydsavlnplk (swbmirgrcd )
NCT02369900 (CTgov)	Phase 2	Shock, Septic \| Hypotension \| Tachycardia	40	Esmolol (Esmolol Infusion)	iapnagsefb(uuxzrxnjlc) = nzoyhxjjjy ekdkeblszx (onxyyccjrb, 0.17) View more	-	28 Jun 2021
				saline (Standard Care, Saline)	iapnagsefb(uuxzrxnjlc) = hucstqwpwa ekdkeblszx (onxyyccjrb, 0.19) View more
NCT02466542 (Pubmed \| Eur J Anaesthesiol)	Phase 4	Pain	-	Esmolol infusion	qqsbcnrsww(rftacfpqbx) = mzkxdiyeyw vdwslwoxis (ebqihoefgb, -13.4 to -0.31)	Positive	08 Apr 2021
NCT03661346 (CTgov)	Phase 2	Hemorrhage \| Chronic sinusitis	28	Esmolol (Esmolol)	onqktoapht(oroohnrshe) = ddvstgcfye lwsigwjgif (dwhlxdvoty, .69) View more	-	08 Feb 2021
				Labetalol (Labetalol)	onqktoapht(oroohnrshe) = vllxpvnxzq lwsigwjgif (dwhlxdvoty, .89) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Esmolol Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation